Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4361831 | 0.98 | TNK2 (0.87) | TNK2IGF1R | |
| SCHEMBL16748918 | 0.95 | TNK2 (0.79) | TNK2IGF1R | |
| SCHEMBL4361113 | 0.91 | TNK2 (1.00) | TNK2 | |
| SCHEMBL16748769 | 0.90 | TNK2 (0.72) | TNK2IGF1R | |
| SCHEMBL23803926 | 0.85 | TNK2 (0.67) | TNK2IGF1R | |
| SCHEMBL8240309 | 0.85 | TNK2 (0.87) | TNK2 | |
| SCHEMBL1129098 | 0.85 | TNK2 (0.72) | TNK2 | |
| SCHEMBL2462683 | 0.85 | TNK2 (0.83) | TNK2IGF1R | |
| SCHEMBL2459340 | 0.84 | IGF1R (1.00) | TNK2IGF1R | |
| SCHEMBL16748841 | 0.84 | TNK2 (0.74) | TNK2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145305-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| EP-4118086-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | Fochon Biosciences, Ltd. (CN) | 2023-01-18 | — | — | EP | disclosed |
| CN-115443277-A | Compounds as kinase inhibitors | 重庆复尚源创医药技术有限公司 | 2022-12-06 | — | — | CN | disclosed |
| WO-2021180107-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2021-09-16 | — | — | WO | disclosed |
| US-9822120-B2 | Protein kinase inhibitors | PHARMASCIENCE INC. (CA) | 2017-11-21 | — | — | US | disclosed |
| US-9822120-B2 | Protein kinase inhibitors | PHARMASCIENCE INC. (CA) | 2017-11-21 | — | — | US | disclosed |
| US-20160280711-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2016-09-29 | — | — | US | disclosed |
| US-20160280711-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2016-09-29 | — | — | US | disclosed |
| WO-2015074138-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE INC. (CA) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145305-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | TNK2 70/4885IGF1R 884/4885 |
| US-20160280711-A1 | Protein Kinase Inhibitors | TEC, LCK, SRC | TNK2 43/4885IGF1R 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.